Results 161 to 170 of about 3,096 (189)

Enfortumab-vedotin/pembrolizumab

Reactions Weekly
  +9 more sources

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

New England Journal of Medicine, 2021
Thomas Powles, Jonathan E Rosenberg, Guru P Sonpavde   +2 more
exaly  

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

New England Journal of Medicine, 2022
Hervé Tilly, Franck Morschhauser, Marek Trneny   +2 more
exaly  

Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma

Nature Reviews Clinical Oncology, 2023
Elizabeth R Plimack
exaly  

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

New England Journal of Medicine, 2022
Stephen M Ansell, John Radford, Monika Długosz-Danecka   +2 more
exaly  

Brentuximab vedotin

Nature Reviews Drug Discovery, 2012
Anas Younes
exaly   +2 more sources

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

Lancet Oncology, The, 2021
Evan Y Yu, Peter H O'donnell, Jae-Lyun Lee   +2 more
exaly  

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

New England Journal of Medicine, 2018
Joseph M Connors, Wojciech Jurczak, Stephen M Ansell   +2 more
exaly  

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

Lancet, The, 2017
Henry M Prince, Youn H Kim, Steven M Horwitz   +2 more
exaly  

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Lancet, The, 2019
Steven Horwitz, Barbara Pro, Tim M Illidge   +2 more
exaly